Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Joseph, McKendrick"'
Autor:
Kate Manos, Geoffrey Chong, Colm Keane, Sze-Ting Lee, Charmaine Smith, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, Melinda Burgess, Niles Elizabeth Nelson, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M. Scott, Allison Barraclough, Joel Wight, Andrew Grigg, Chun Yew Fong, Eliza A. Hawkes
Publikováno v:
Leukemia. 37:1092-1102
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5fa424bbaa5539fb2036c364c19ae70
https://doi.org/10.1038/s41375-023-01863-7
https://doi.org/10.1038/s41375-023-01863-7
Autor:
Prasad Cooray, Belinda Lee, Rachel Wong, Ben Tran, Jayesh Desai, Sumitra Ananda, Rachel Delahunty, Margaret Lee, Hui-Li Wong, Peter Gibbs, Jeanne Tie, Julie Johns, Suzanne Kosmider, Joseph McKendrick
Publikováno v:
Internal Medicine Journal. 50:165-172
Background In the treatment of metastatic colorectal cancer (mCRC), exposure to all three active cytotoxic agents, 5-fluorouracil/capecitabine, irinotecan and oxaliplatin, improves overall survival. The addition of biologic agents (bevacizumab and ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f0c2c300fe76d04543bd09380d6377b
https://doi.org/10.1111/imj.14288
https://doi.org/10.1111/imj.14288
Autor:
Roberto Buzzoni, W.P. Yong, S. Reingold, Joseph McKendrick, G.J.M. Creemers, Fernando Rivera, Dewi Vernerey, David Cunningham, G. Ravit, E. Van Cutsem, Jin-Tung Liang, A. de Gramont, Pia Österlund, G. Bodoky, Thierry André, J. Tabernero, W. Scheithauer, Randi Isaacs, Manel Rakez, S-A. Im, G. Fountzilas
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2020, 31, pp.246-256. ⟨10.1016/j.annonc.2019.12.006⟩
Annals of Oncology, Elsevier, 2020, 31, pp.246-256. ⟨10.1016/j.annonc.2019.12.006⟩
Background The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cfd78f076d1d408cc0e7322b124c0ad
https://doi.org/10.1016/j.annonc.2019.12.006
https://doi.org/10.1016/j.annonc.2019.12.006
Autor:
Azim Jalali, Jeanne Tie, Rachel Wong, Sarah J. Banks, Lucy Gately, Belinda Lee, Margaret Lee, Matthew Loft, Grace Gard, Catherine Dunn, Adnan Khattak, Hui-Li Wong, Ross Jennens, Justin M. C. Yeung, Peter Gibbs, Joseph McKendrick, Suzanne Kosmider, Sumitra Ananda, L. Lim, Jeremy Shapiro
Publikováno v:
Current problems in cancer. 46(2)
For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f0ed897b07bcfd6a00b30a5592c890d
https://pubmed.ncbi.nlm.nih.gov/34565601
https://pubmed.ncbi.nlm.nih.gov/34565601
Autor:
Rachel Wong, Sarat Chander, Mathias Bressel, Trevor Leong, Samuel Y Ngan, Sweet Ping Ng, Alexander G. Heriot, Julie Chu, Michael Michael, Malcolm Steel, Joseph McKendrick, William K. Murray
Publikováno v:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 155
Background and purpose The chemotherapy exposure during chemoradiotherapy for rectal cancer is adequate for radiosensitization but suboptimal for treatment of distant micrometastasis. This study aimed to determine tolerability, dose intensity, respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::199f4b2fdff396c8164e33da6e5450e7
https://pubmed.ncbi.nlm.nih.gov/33065186
https://pubmed.ncbi.nlm.nih.gov/33065186
Autor:
Phillip Parente, Jennifer A. Soon, Ruth Lawrence, Ian D. Davis, Joseph McKendrick, Carmel Pezaro, Javier Torres, Angelyn Anton
Publikováno v:
Supportive Care in Cancer. 27:373-382
Testicular seminomas occur in young men and are highly curable. Toxicities following treatment for men with extensive stage II-III seminomas may cause long-term morbidities. However, it is not clear whether the risk of late effects also increases fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103c0e2efe898cffa6e9368629ac0b78
https://doi.org/10.1007/s00520-018-4492-7
https://doi.org/10.1007/s00520-018-4492-7
Autor:
Trevor Leong, Samuel Y Ngan, Julie Chu, Michael Michael, Thomas G. Bird, Sarat Chander, Mathias Bressel, Prasad Cooray, Malcolm Steel, Michael Jefford, Joseph McKendrick, Alexander G. Heriot
Publikováno v:
Acta Oncologica. 56:646-652
Optimal initial management of rectal carcinoma with synchronous metastases (RCSM) is controversial - both for patients being treated with curative and palliative intent. This study aims to evaluate the use of an upfront treatment strategy combining F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb055acc47e797ad1259f5f22e360de
https://doi.org/10.1080/0284186x.2017.1296584
https://doi.org/10.1080/0284186x.2017.1296584
Autor:
Eliza A Hawkes, Tineke Fancourt, Joel Wight, Andrew M. Scott, Wendi Lin, Kate Manos, William Renwick, Geoffrey Chong, Joseph McKendrick, Charmaine Smith, Niles Elizabeth Nelson, Andrew Grigg, Piers Blombery, Chun Yew Fong, Allison Barraclough, Colm Keane, Sze Ting Lee, Leonid Churilov, Joanne Hawking
Publikováno v:
Blood. 136:43-44
Background: Novel strategies are needed to improve upon the 60% cure rate of upfront R-CHOP in advanced DLBCL. Single-agent immune checkpoint inhibition (ICI) has limited efficacy in heavily pre-treated DLBCL (response rate Avelumab (Av) is an anti-P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74581e1587540146ad370c9ead949ba5
https://doi.org/10.1182/blood-2020-136024
https://doi.org/10.1182/blood-2020-136024
Autor:
Rowan Doig, Eliza A Hawkes, Babak Tamjid, Anthony P. Schwarer, Joseph McKendrick, Philip James, Patrick Hosking
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 13:226-233
Aim Relapsed/refractory (R/R) aggressive lymphoma outcomes are poor. There is no standard treatment. PACEBOM (prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine and methotrexate) has shown efficacy for several lymphoma sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfda1b3f00b3d851067f0da94b20430b
https://doi.org/10.1111/ajco.12611
https://doi.org/10.1111/ajco.12611
Autor:
Lisa Dobbyn, Jeanne Tie, Belinda Lee, Rachel Wong, Ian Faragher, Ian T. Jones, Michael Christie, Sumitra Ananda, Nicholas Papadopoulos, Bert Vogelstein, Yuxuan Wang, Natalie Silliman, Lu Li, Jin Hee Cho, Margaret Lee, Mary J. Schaeffer, Janine Ptak, Joshua D. Cohen, Peter Gibbs, Cristian Tomasetti, Kenneth W. Kinzler, Joseph McKendrick, Koen Simons, Suzanne Kosmider
Publikováno v:
JAMA oncology. 5(12)
Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant treatment cannot currently be dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea8069bcd610251cae3a08272872c372
https://pubmed.ncbi.nlm.nih.gov/32239189
https://pubmed.ncbi.nlm.nih.gov/32239189